|Bid||25.28 x 700|
|Ask||25.56 x 500|
|Day's Range||27.06 - 27.48|
|52 Week Range||23.29 - 29.93|
|PE Ratio (TTM)||357.89|
|Earnings Date||Apr 25, 2018 - Apr 30, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||31.60|
BSX Stock Recovers after a Robust 4Q17: What's to Come? In 4Q17, Boston Scientific’s (BSX) Cardiovascular business segment reported sales of $913 million, representing above-market YoY (year-over-year) growth of ~8.7%. The segment’s IC (interventional cardiology) division reported sales of $636 million in 4Q17, which represented a YoY rise of ~8.8%, including the impact of ~2.8% from its acquisition of Symetis in May 2017.
BSX Stock Recovers after a Robust 4Q17: What's to Come? In 4Q17, Boston Scientific’s (BSX) Cardiovascular segment registered strong YoY (year-over-year) sales growth of ~8.7% on a reported basis. The segment’s PI (peripheral interventions) division came in at $277 million, registering a YoY rise of 8.4%, whereas the IC (interventional cardiology) division reported sales of $636 million, a YoY rise of ~8.8%. The operational sales growth of BSX’s Cardiovascular segment came in at ~6.8%.
BSX Stock Recovers after a Robust 4Q17: What's to Come? In 4Q17, Boston Scientific’s (BSX) MedSurg segment witnessed double-digit YoY (year-over-year) growth of ~14.2%, on a reported basis. The segment’s operational sales growth came in at ~12.8%, whereas it grew ~11.2% on an organic basis.
BSX Stock Recovers after a Robust 4Q17: What's to Come? Boston Scientific released its 4Q17 and 2017 earnings results on February 1, 2018. During its earnings release, the company announced that it expected to relaunch its Lotus device in European and US markets in 2019.
This could indicate that investors who seek to profit from falling equity prices are not currently targeting BSX. Over the last one-month, outflows of investor capital in ETFs holding BSX totaled $375 million.
Boston Scientific's (BSX) major Millipede investment might cement the company's position in the emerging mitral regurgitation field under its structural heart business.
Abbott Laboratories (ABT) posted a strong earnings results on January 24, 2018, surpassing Wall Street estimates and posting earnings at the higher end of its guidance. ABT stock registered a rise of more than 4% that day. Abbott Laboratories had an eventful year in 2017, with a number of key strategic acquisitions, divestitures, and product launches.
Boston Scientific reported adjusted income of 34 cents a share on $2.41 billion in fourth-quarter sales.
What's Next for Abbott Laboratories after a Stellar 2017?The impact of 4Q17 earnings release on ABT’s stock price performance
Sirtex Medical Systems is an Australia-based life sciences company with a presence around the globe. The company is focused on interventional oncology therapies and is a global leader in radioembolization. Radioembolization is a minimally invasive therapy for the treatment of liver cancer.